Title:
PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTITUMOR EFFECT BY IMMUNE CHECKPOINT INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2019/107389
Kind Code:
A1
Abstract:
[Problem] The purpose of the present invention is to provide a pharmaceutical composition for enhancing an antitumor effect by an immune checkpoint inhibitor. [Solution] Provided is a pharmaceutical composition for enhancing an antitumor effect by an immune checkpoint inhibitor, the pharmaceutical composition containing 5-aminolevulinic acid (ALA) as an active ingredient.
More Like This:
Inventors:
TANAKA TOHRU (JP)
ITO HIDENORI (JP)
RII KO (JP)
ITO HIDENORI (JP)
RII KO (JP)
Application Number:
PCT/JP2018/043704
Publication Date:
June 06, 2019
Filing Date:
November 28, 2018
Export Citation:
Assignee:
SBI PHARMACEUTICALS CO LTD (JP)
NAT CT CHILD HEALTH & DEV (JP)
NAT CT CHILD HEALTH & DEV (JP)
International Classes:
A61K31/197; A61K33/06; A61K33/24; A61K33/26; A61K33/30; A61K33/34; A61K39/395; A61K45/00; A61K47/12; A61P35/00; A61P43/00
Domestic Patent References:
| WO2017103280A1 | 2017-06-22 | |||
| WO2017103283A1 | 2017-06-22 | |||
| WO2015129535A1 | 2015-09-03 |
Foreign References:
| JP2011016753A | 2011-01-27 | |||
| JP5885764B2 | 2016-03-15 | |||
| JPS5611548B2 | 1981-03-14 |
Other References:
WANG, S. ET AL.: "5-aminolevulinic acid-mediated sonodynamic therapy reverses macrophage and dendritic cell passivity in murine melanoma xenografts", ULTRASOUND MED BIOL., vol. 40, no. 9, 2014, pages 2125 - 2133, XP55616078
KEE, D. ET AL.: "Immunotherapy of melanoma", EUR J SURG ONCOL, vol. 43, no. 3, March 2017 (2017-03-01), pages 594 - 603, XP029914020, DOI: 10.1016/j.ejso.2016.07.014
WATASE, ERIKA ET AL.: "Effects on the immune checkpoint factors by combination photodynamic therapy with aminolevulinic acid for malignant glioma", NIHON IKA DAIGAKU IGAKKAI ZASSHI, vol. 13, no. 4, October 2017 (2017-10-01), pages 248, XP009519894, DOI: 10.1272/manms.13.243
HOU, J. ET AL.: "5-aminolevulinic acid with ferrous iron induces permanent cardiac allograft acceptance in mice via induction of regulatory cells", J HEART LUNG TRANSPLANT, vol. 34, no. 2, 2015, pages 254 - 263, XP029220929, DOI: 10.1016/j.healun.2014.09.037
NAT REV CANCER., vol. 12, no. 4, 22 March 2012 (2012-03-22), pages 252 - 64
ANN TRANSL MED., vol. 3, no. 18, October 2015 (2015-10-01), pages 267
PROC NATL ACAD SCI USA., vol. 114, no. 5, 31 January 2017 (2017-01-31), pages E761 - E770
AM J PHYSIOL RENAL PHYSIOL., vol. 305, no. 8, 15 October 2013 (2013-10-15), pages F1149 - 57
AM J PHYSIOL CELL PHYSIOL., vol. 308, no. 8, 15 April 2015 (2015-04-15), pages C665 - 72
J HEART LUNG TRANSPLANT., vol. 34, no. 2, February 2015 (2015-02-01), pages 254 - 63
See also references of EP 3673904A4
KEE, D. ET AL.: "Immunotherapy of melanoma", EUR J SURG ONCOL, vol. 43, no. 3, March 2017 (2017-03-01), pages 594 - 603, XP029914020, DOI: 10.1016/j.ejso.2016.07.014
WATASE, ERIKA ET AL.: "Effects on the immune checkpoint factors by combination photodynamic therapy with aminolevulinic acid for malignant glioma", NIHON IKA DAIGAKU IGAKKAI ZASSHI, vol. 13, no. 4, October 2017 (2017-10-01), pages 248, XP009519894, DOI: 10.1272/manms.13.243
HOU, J. ET AL.: "5-aminolevulinic acid with ferrous iron induces permanent cardiac allograft acceptance in mice via induction of regulatory cells", J HEART LUNG TRANSPLANT, vol. 34, no. 2, 2015, pages 254 - 263, XP029220929, DOI: 10.1016/j.healun.2014.09.037
NAT REV CANCER., vol. 12, no. 4, 22 March 2012 (2012-03-22), pages 252 - 64
ANN TRANSL MED., vol. 3, no. 18, October 2015 (2015-10-01), pages 267
PROC NATL ACAD SCI USA., vol. 114, no. 5, 31 January 2017 (2017-01-31), pages E761 - E770
AM J PHYSIOL RENAL PHYSIOL., vol. 305, no. 8, 15 October 2013 (2013-10-15), pages F1149 - 57
AM J PHYSIOL CELL PHYSIOL., vol. 308, no. 8, 15 April 2015 (2015-04-15), pages C665 - 72
J HEART LUNG TRANSPLANT., vol. 34, no. 2, February 2015 (2015-02-01), pages 254 - 63
See also references of EP 3673904A4
Attorney, Agent or Firm:
NANJO, Masahiro et al. (JP)
Download PDF: